Drug

Pharmacologic Class

Indication

More Information
Cardiovascular Disease
Furoscix (furosemide injection) Loop diuretic Treatment of congestion due to fluid overload in adult patients with New York Heart Association Class II and Class III chronic heart failure. FDA Approves Wearable Furosemide Delivery System Furoscix for Outpatient Use
Musculoskeletal Disorders
Rinvoq (upadacitinib) Janus kinase inhibitor Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor blocker therapy. Rinvoq Approved for Active Non-Radiographic Axial Spondyloarthritis
Oncology
Imjudo (tremelimumab-actl) Human monoclonal antibody that targets the activity of cytotoxic T-lymphocyte-associated protein 4 In combination with durvalumab, for the treatment of adults with unresectable hepatocellular carcinoma. Imjudo Plus Imfinzi Approved for Unresectable Hepatocellular Carcinoma
Tecvayli (teclistamab-cqyv) Bispecific B-cell maturation antigen-directed CD3 T-cell engager Treatment of adult patients with relapsed or refractory multiple myeloma, who previously received 4 or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody. Tecvayli Approved for Relapsed or Refractory Multiple Myeloma

Topics:

Axial Spondyloarthritis Cardiovascular Disease CHF and Arrhythmias Colorectal And Other GI Cancers Multiple Myeloma Musculoskeletal Disorders Oncology Renal Cell Carcinoma